Tumor responses according to irRECIST.
| Cohort A (MSI-H) | Cohort B (MSS) | |
|---|---|---|
| (n = 10) | (n = 40) | |
| Best response, n (%) | ||
| CR | 1 (10.0) | 0 (0) |
| PR | 4 (40.0) | 4 (10.0) |
| SD | 4 (40.0) | 14 (35.0) |
| Disease progression | 1 (10.0) | 21 (52.5) |
| Not evaluated | 0 (0) | 1 (2.5) |
| ORR, % (95% CI) | 50.0 (18.7–81.3) | 10.0 (2.8–23.7) |
| DCR, % (95% CI) | 90.0 (55.5–99.7) | 45.0 (29.3–61.5) |
| DOR, months, median (95% CI) | NR (7.9–NR) | 9.0 (1.7–9.0) |